Adjuvant immunotherapy for melanoma
- PMID: 33595889
- DOI: 10.1002/jso.26329
Adjuvant immunotherapy for melanoma
Abstract
Surgical resection is the treatment for early cutaneous melanoma and is often curative. Some patients, however, will subsequently relapse. High-risk features in the primary tumor and regional lymph node metastasis highlight patient subsets that are at increased risk for recurrent disease. Immunotherapy in the form of checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab have been shown to improve recurrence-free survival for node-positive melanoma in the adjuvant setting and will be the focus of this review.
Keywords: Stage III; adjuvant therapy; immunotherapy; melanoma; targeted therapy.
© 2020 Wiley Periodicals LLC.
References
REFERENCES
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.
-
- Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472-492.
-
- Coit DG, Thompson JA, Albertini MR, et al. Cutaneous Melanoma, Version 2.2019. NCCN Clin Pract Guideline Oncol. 2019;17:367.
-
- Eggermont AMM, Dummer R. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients. Eur J Cancer. 2017;86:101-105.
-
- Bello DM, Ariyan CE. Adjuvant therapy in the treatment of melanoma. Ann Surg Oncol. 2018;25:1807-1813.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical